Methotrexate
Yıl: 2022 Cilt: 56 Sayı: 1 Sayfa Aralığı: 17 - 20 Metin Dili: İngilizce DOI: 10.4274/turkderm.galenos.2022.48716 İndeks Tarihi: 18-07-2022
Methotrexate
Öz: Methotrexate is a drug used in the treatment of psoriasis and psoriatic arthritis. It shows its effect by binding to dihydrofolate reductase,
reducing purine synthesis and cell proliferation. When used as a monotherapy, methotrexate shows its effect late and achieves a 50-75%
recovery in skin lesions. Patients using methotrexate should periodically be monitored for toxicity with relevant laboratory parameters. Its use
in combination with folic acid reduces the risk of toxicity. Using it in combination with cyclosporine in low doses may lower the toxicity risk of
both. Its use in combination with phototherapy and acitretin has been found considerably effective.
Anahtar Kelime: Metotreksat
Öz: Metotreksat psoriasis ve psoriatik artrit tedavisinde kullanılan etkisini dihidrofolat redüktaza bağlanarak purin sentezini ve hücre proliferasyonu
azaltarak gösteren bir ilaçtır. Metotreksat tedavide monoterapi olarak kullanıldığında etkisi geç başlar. Monoterapi olarak kullanıldığında
deri lezyonlarında %50-75 oranında iyileşme sağlar. Metotreksat kullanan hastalar toksisite açısından belirli periyotlarda ilgili laboratuvar
parametreleri ile izlenmelidir. Folik asitle birlikte kullanılması toksisite riskini azaltır. Siklosporin ile birlikte düşük dozlarda kullanılması her iki
ilacın da toksisite riskini azaltabilir. İlacın fototerapi ve asitretin ile birlikte kullanımının oldukça etkili olduğu bulunmuştur.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Nast A, Amelunxen L, Augustin M, et al.: S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 1 - Systemic treatment. J Dtsch Dermatol Ges 2018;16:645-69.
- 2. Menter A, Korman NJ, Elmets CA, et al.: Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4.Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61:451-85.
- 3. Cronstein B: How does methotrexate suppress inflammation? Clin Exp Rheumatol 2010;28(Suppl61):S21-3.
- 4. Friedman B, Cronstein B: Methotrexate Mechanism in Treatment of Rheumatoid Arthritis Joint Bone Spine 2019;86:301-7.
- 5. Meephansan J, Ruchusatsawat K, Sindhupak W, Thorner PS, Wongpiyabovorn J: Effect of methotrexate on serum levels of IL-22 in patients with psoriasis. Eur J Dermatol 2011;21:501-4.
- 6. Baran W, Batycka-Baran A, Zychowska M, Bieniek A, Szepietowski JC: Folate supplementation reduces the side effects of methotrexate therapy forpsoriasis. Expert Opin Drug Saf 2014;13:1015-21.
- 7. Bath RK, Brar NK, Forouhar FA, Wu GY: A review of methotrexate-associated hepatotoxicity. J Dig Dis 2014;15:517-24.
- 8. Rademaker M, Gupta M, Andrews M, et al.: The Australasian Psoriasis Collaboration View on Methotrexate for Psoriasis in the Australasian Setting Australas J Dermatol 2017;58:166-70.
- 9. NICE. Psoriasis: assessment and management of psoriasis. NICE guidelines [CG153]. London: Royal College of Physicians (UK) CTI - National Institute for Health and Clinical Excellence: Guidance; 2012 [updated 20141024]. Available from: http://www.nice.org.uk/guidance/cg153/evidence/fullguideline-188351533
- 10. Weinstein GD, Frost P: Methotrexate for psoriasis. A new therapeutic schedule. Arch Dermatol 1971;103:33-8.
- 11. Nyfors A, Brodthagen H: Methotrexate for psoriasis in weekly oral doses without any adjunctive therapy. Dermatologica 1970;140:345-55.
- 12. Flytström I, Stenberg B, Svensson A, Bergbrant IM: Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008;158:116-21.
- 13. Nast A, Sporbeck B, Rosumeck S, et al.: Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action. J Invest Dermatol 2013;133:1963-70.
- 14. Aydin F, Canturk T, Senturk N, Turanli AY: Methotrexate and ciclosporin combination for the treatment of severe psoriasis. Clin Exp Dermatol 2006;31:520-4.
- 15. Clark CM, Kirby B, Morris AD, et al.: Combination treatment with methotrexate and ciclosporin for severe recalcitrant psoriasis. Br J Dermatol 1999;141:279-82.
- 16. Asawanonda P, Nateetongrungsak Y: Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study. J Am Acad Dermatol 2006;54:1013-8.
- 17. Morison WL, Momtaz K, Parrish JA, Fitzpatrick TB: Combined methotrexatePUVA therapy in the treatment of psoriasis. J Am Acad Dermatol 1982;6: 6-51.
- 18. Lowenthal KE, Horn PJ, Kalb RE: Concurrent use of methotrexate and acitretin revisited. J Dermatolog Treat 2008;19:22-6.
- 19. Zachariae C, Mørk NJ, Reunala T, et al.: The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol 2008;88:495-501.
- 20. Maini RN, Breedveld FC, Kalden JR, et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
- 21. Cheng HS, Rademaker M: Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography. Psoriasis (Auckl) 2018;8:21-9.
- 22. MacDonald A, Burden AD: Noninvasive monitoring for methotrexate hepatotoxicity. Br J Dermatol 2005;152:405-8.
- 23. Chalmers RJ, Kirby B, Smith A, et al.: Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 2005;152:444-50.
- 24. Raaby L, Zachariae C, Østensen M, et al.: Methotrexate Use and Monitoring in Patients With Psoriasis: A Consensus Report Based on a Danish Expert Meeting Acta Derm Venereol 2017;97:426-32.
- 25. Kaur I, Dogra S, De D, Kanwar AJ: Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India. Pediatr Dermatol 2008;25:184-8.
- 26. Pannu AK: Methotrexate overdose in clinical practice. Curr Drug Metab 2019;20:714-9.
- 27. Gelfand JM, Armstrong AW, Bell S, et al.: National Psoriasis Foundation COVID-19 task force guidance for management of psoriatic disease during the pandemic: Version 1. J Am Acad Dermatol 2020;83:1704-16.
| APA | senturk n (2022). Methotrexate. , 17 - 20. 10.4274/turkderm.galenos.2022.48716 |
| Chicago | senturk nilgun Methotrexate. (2022): 17 - 20. 10.4274/turkderm.galenos.2022.48716 |
| MLA | senturk nilgun Methotrexate. , 2022, ss.17 - 20. 10.4274/turkderm.galenos.2022.48716 |
| AMA | senturk n Methotrexate. . 2022; 17 - 20. 10.4274/turkderm.galenos.2022.48716 |
| Vancouver | senturk n Methotrexate. . 2022; 17 - 20. 10.4274/turkderm.galenos.2022.48716 |
| IEEE | senturk n "Methotrexate." , ss.17 - 20, 2022. 10.4274/turkderm.galenos.2022.48716 |
| ISNAD | senturk, nilgun. "Methotrexate". (2022), 17-20. https://doi.org/10.4274/turkderm.galenos.2022.48716 |
| APA | senturk n (2022). Methotrexate. Türkderm Türk deri hastalıkları ve frengi arşivi, 56(1), 17 - 20. 10.4274/turkderm.galenos.2022.48716 |
| Chicago | senturk nilgun Methotrexate. Türkderm Türk deri hastalıkları ve frengi arşivi 56, no.1 (2022): 17 - 20. 10.4274/turkderm.galenos.2022.48716 |
| MLA | senturk nilgun Methotrexate. Türkderm Türk deri hastalıkları ve frengi arşivi, vol.56, no.1, 2022, ss.17 - 20. 10.4274/turkderm.galenos.2022.48716 |
| AMA | senturk n Methotrexate. Türkderm Türk deri hastalıkları ve frengi arşivi. 2022; 56(1): 17 - 20. 10.4274/turkderm.galenos.2022.48716 |
| Vancouver | senturk n Methotrexate. Türkderm Türk deri hastalıkları ve frengi arşivi. 2022; 56(1): 17 - 20. 10.4274/turkderm.galenos.2022.48716 |
| IEEE | senturk n "Methotrexate." Türkderm Türk deri hastalıkları ve frengi arşivi, 56, ss.17 - 20, 2022. 10.4274/turkderm.galenos.2022.48716 |
| ISNAD | senturk, nilgun. "Methotrexate". Türkderm Türk deri hastalıkları ve frengi arşivi 56/1 (2022), 17-20. https://doi.org/10.4274/turkderm.galenos.2022.48716 |
